SakakinCAS# 21082-33-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 21082-33-7 | SDF | Download SDF |
PubChem ID | 70700401 | Appearance | White-beige powder |
Formula | C13H18O7 | M.Wt | 286.3 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Synonyms | 1-O-β-D-Glucosylorcinol; Sakakin | ||
Solubility | Soluble in ethan | ||
Chemical Name | (2R,3S,4S,5R)-2-(hydroxymethyl)-6-(3-hydroxy-5-methylphenoxy)oxane-3,4,5-triol | ||
SMILES | CC1=CC(=CC(=C1)OC2C(C(C(C(O2)CO)O)O)O)O | ||
Standard InChIKey | YTXIGTCAQNODGD-HENWMNBSSA-N | ||
Standard InChI | InChI=1S/C13H18O7/c1-6-2-7(15)4-8(3-6)19-13-12(18)11(17)10(16)9(5-14)20-13/h2-4,9-18H,5H2,1H3/t9-,10-,11+,12-,13?/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Orcinol glucoside(Sakakin) shows potent antioxidative and anxiolytic activities without sedative effects, it can improve depressive behaviour in chronic unpredictable mild stress (CUMS) rats by downregulating HPA axis hyperactivity and increasing BDNF expression and ERK1/2 phosphorylation in the hippocampus. |
Targets | ERK | BDNF | CORT |
In vitro | Antioxidative phenols and phenolic glycosides from Curculigo orchioides.[Pubmed: 16079552]Chem Pharm Bull (Tokyo). 2005 Aug;53(8):1065-7.A new orcinol glucoside, orcinol-1-O-beta-D-apiofuranosyl-(1-->6)-beta-D-glucopyranoside (3), was isolated from the rhizomes of Curculigo orchioides GAERTN., together with seven known compounds: orcinol glucoside (1), orcinol-1-O-beta-D-glucopyranosyl-(1-->6)-beta-D-glucopyranoside (2), curculigoside (Sakakin,4), curculigoside B (5), curculigoside C (6), 2,6-dimethoxyl benzoic acid (7), and syringic acid (8). |
In vivo | Orcinol glucoside produces antidepressant effects by blocking the behavioural and neuronal deficits caused by chronic stress.[Pubmed: 23838013 ]Eur. Neuropsychopharmacol. ,2014 ,24(1): 172-80.This study focused on the antidepressant potential of orcinol glucoside (Sakakin,OG) and its possible mechanisms of action. |
Animal Research | Anxiolytic effects of orcinol glucoside and orcinol monohydrate in mice.[Pubmed: 25429891 ]Pharm. Biol., 2015, 53(6):876-81.Anxiety is a common psychological disorder, often occurring in combination with depression, but therapeutic drugs with high efficacy and safety are lacking. Orcinol glucoside (Sakakin,OG) was recently found to have an antidepressive action.
To study the therapeutic potential of OG and orcinol monohydrate (OM) as anxiolytic agents.
|
Sakakin Dilution Calculator
Sakakin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4928 mL | 17.4642 mL | 34.9284 mL | 69.8568 mL | 87.321 mL |
5 mM | 0.6986 mL | 3.4928 mL | 6.9857 mL | 13.9714 mL | 17.4642 mL |
10 mM | 0.3493 mL | 1.7464 mL | 3.4928 mL | 6.9857 mL | 8.7321 mL |
50 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.3971 mL | 1.7464 mL |
100 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.6986 mL | 0.8732 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- CP 471474
Catalog No.:BCC2373
CAS No.:210755-45-6
- 7,8-Dihydroxy-4-Methylcoumarin
Catalog No.:BCC8290
CAS No.:2107-77-9
- 5,7-Dihydroxy-4-Methylcoumarin
Catalog No.:BCC8284
CAS No.:2107-76-8
- PD 168568 dihydrochloride
Catalog No.:BCC7702
CAS No.:210688-56-5
- 6alpha-Hydroxylycopodine
Catalog No.:BCN7403
CAS No.:21061-92-7
- 1,11b-Dihydro-11b-hydroxymaackiain
Catalog No.:BCN3914
CAS No.:210537-05-6
- 1,11b-Dihydro-11b-hydroxymedicarpin
Catalog No.:BCN3913
CAS No.:210537-04-5
- Sitaxentan sodium
Catalog No.:BCC4495
CAS No.:210421-74-2
- Odoratin-7-O-beta-D-glucopyranoside
Catalog No.:BCN8089
CAS No.:210413-47-1
- Spiradine F
Catalog No.:BCN4915
CAS No.:21040-64-2
- Cinnamyl acetate
Catalog No.:BCN4914
CAS No.:21040-45-9
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- Org 12962 hydrochloride
Catalog No.:BCC7718
CAS No.:210821-63-9
- W-84 dibromide
Catalog No.:BCC6682
CAS No.:21093-51-6
- CART (62-76) (rat, human)
Catalog No.:BCC6008
CAS No.:210978-19-1
- BMY 7378
Catalog No.:BCC5063
CAS No.:21102-95-4
- Mahanimbine
Catalog No.:BCN3174
CAS No.:21104-28-9
- SB 265610
Catalog No.:BCC5936
CAS No.:211096-49-0
- Marsformoxide B
Catalog No.:BCN6687
CAS No.:2111-46-8
- Sobetirome
Catalog No.:BCC1957
CAS No.:211110-63-3
- Rubranol
Catalog No.:BCN4917
CAS No.:211126-61-3
- 9,17-Octadecadiene-12,14-diyne-1,11,16-triol
Catalog No.:BCN1497
CAS No.:211238-60-7
- m-Chlorophenylbiguanide hydrochloride
Catalog No.:BCC6650
CAS No.:2113-05-5
- R18
Catalog No.:BCC2383
CAS No.:211364-78-2
Orcinol glucoside produces antidepressant effects by blocking the behavioural and neuronal deficits caused by chronic stress.[Pubmed:23838013]
Eur Neuropsychopharmacol. 2014 Jan;24(1):172-80.
This study focused on the antidepressant potential of orcinol glucoside (OG) and its possible mechanisms of action. We established a depressed rat model using 3 consecutive weeks of chronic unpredictable mild stress (CUMS). The antidepressant-like effect of OG was revealed using the sucrose preference test, the open field test, the forced swimming test (FST), and the tail suspension test (TST). The activity of the hypothalamic-pituitary-adrenal (HPA) axis was evaluated by detecting the serum corticosterone (CORT) concentrations and mRNA expression of corticotrophin-releasing hormone (CRH) in the hypothalamus. The protein expression levels of brain-derived neurotrophic factor (BDNF) and total phosphorylated-ERK1/2 were detected by western blot. The results showed that OG treatment (1.5, 3, or 6mg/kg) alleviated the depression-like behaviour of rats under CUMS, as indicated by the increased sucrose preference and the decreased immobility in both the FST and TST, although the rearing frequency in the open field test increased only in the group that received the lowest dose (1.5mg/kg OG). Rats that received OG treatment exhibited reduced serum CORT levels and CRH mRNA expression in the hypothalamus, suggesting that the hyperactivity of the HPA axis in CUMS rats was reversed by OG treatment. Moreover, OG treatment upregulated the protein levels of BDNF and phosphorylated-ERK1/2 in the hippocampus, even above control levels. Our findings suggest that OG improved depressive behaviour in CUMS rats by downregulating HPA axis hyperactivity and increasing BDNF expression and ERK1/2 phosphorylation in the hippocampus.
Antioxidative phenols and phenolic glycosides from Curculigo orchioides.[Pubmed:16079552]
Chem Pharm Bull (Tokyo). 2005 Aug;53(8):1065-7.
A new orcinol glucoside, orcinol-1-O-beta-D-apiofuranosyl-(1-->6)-beta-D-glucopyranoside (3), was isolated from the rhizomes of Curculigo orchioides GAERTN., together with seven known compounds: orcinol glucoside (1), orcinol-1-O-beta-D-glucopyranosyl-(1-->6)-beta-D-glucopyranoside (2), curculigoside (4), curculigoside B (5), curculigoside C (6), 2,6-dimethoxyl benzoic acid (7), and syringic acid (8). The structures of these compounds were elucidated using spectroscopic methods. The antioxidant activities of these isolated compounds were evaluated by colorimetric methods based on their scavenging effects on hydroxyl radicals and superoxide anion radicals, respectively. All the compounds showed potent antioxidative activities and the structure-activity relationship is discussed.
Anxiolytic effects of orcinol glucoside and orcinol monohydrate in mice.[Pubmed:25429891]
Pharm Biol. 2015 Jun;53(6):876-81.
CONTEXT: Anxiety is a common psychological disorder, often occurring in combination with depression, but therapeutic drugs with high efficacy and safety are lacking. Orcinol glucoside (OG) was recently found to have an antidepressive action. OBJECTIVE: To study the therapeutic potential of OG and orcinol monohydrate (OM) as anxiolytic agents. MATERIALS AND METHODS: Anxiolytic effects in mice were measured using the elevated plus-maze, hole-board, and open-field tests. Eight groups of mice were included in each test. Thirty minutes before each test, mice in each group received one oral administration of OG (5, 10, or 20 mg/kg), OM (2.5, 5, or 10 mg/kg), the positive control diazepam (1 or 5 mg/kg), or control vehicle. Each mouse underwent only one test. Uptake of orcinol (5 mg/kg) in the brain was qualitatively detected using the HPLC-MS method. RESULTS: OG (5, 10, and 20 mg/kg) and OM (2.5 and 5 mg/kg) increased the time spent in open arms and the number of entries into open arms in the elevated plus-maze test. OG (5 and 10 mg/kg) and OM (2.5 and 5 mg/kg) increased the number of head-dips in the hole-board test. At all tested doses, OG and OM did not significantly affect the locomotion of mice in the open-field test. Orcinol could be detected in the mouse brain homogenates 30 min after oral OM administration, having confirmed that OM is centrally active. DISCUSSION AND CONCLUSION: The results demonstrated that OG and OM are anxiolytic agents without sedative effects, indicating their therapeutic potential for anxiety.